Home > Back to Publisher > Report Information

The World Market for Cancer Therapeutics and Biotherapeutics, 3rd. Edition

Kalorama Information
May 1, 2009
280 Pages - SKU: KLI2218043

Attention: There is an updated edition available for this report.

Abstract Table of Contents Search inside this report Related Reports

Countries covered: Global

Worldwide cancer affects more than 10 million people each year. This number is expected to increase by 2.4% by 2020 to 14 million each year. Worldwide approximately 22 million people are living with cancer and nearly 7 million people die. The most common cancers affecting the world include lung, breast, colon/rectum, stomach, liver, prostate, cervical, esophageal, and bladder.

This Kalorama Information report - The World Market for Cancer Therapeutics and Biotherapeutics - focuses on several segments for cancer treatment. The report covers both currently marketed and late stage development cancer products. Revenues for each current market segment were generated using dollar and unit sales for each product.

The following approaches to cancer therapeutics are covered in the report:

Biotherapeutics
- Monoclonal Antibodies
- Interleukins/ Interferons
- Kinases and Other Treatments
Chemotherapy
- Alkylating Agents
- Antimetabolites
- Cytotoxic Agents
- Plant Derivatives
Hormone Therapy
- Corticosteroids
- Hormone Antagonists/ Antagonists
- Aromatase Inhibitors
- SERMS

The report includes market share by type of cancer and market share by company for each of the three major segments. It also includes statistical information for cancers by type worldwide, with special emphasis on the U.S. market. Specifically, cancers where there are current products available or are in development and/or have significant incidence/mortality rates are profiled. The market segments provide an overview, description of products on the market, list of products in late-stage development, market estimates and forecasts, and competitive analysis of leading providers. The report also includes current issues and trends affecting the industry.

A Primary Research Effort

The information for this report was gathered using both primary and secondary research including comprehensive research of secondary sources such as company literature, databases, investment reports, and medical and business journals. Telephone interviews and email correspondence were the primary method of gathering information. For the purpose of this study Kalorama Information conducted interviews with key industry officials, consultants, health care providers, and government personnel. These sources were the primary basis in gathering information specifically relating to revenue and market share data presented in this report. Specific interviews with pharmaceutical company representatives included marketing directors, division managers, and product representatives. All market data pertains to the world market at the manufacturers’ level.

Coverage of the Most Recent Product and Trends

The base year for data was 2008. Historical data was provided for the years 2004 through 2007, with forecast data provided for 2009 through 2013. Compound annual growth rates (CAGRs) are provided for the 2004-2008, 2009-2013 and 2004-2013 periods for each industry segment covered. Competitive analysis is provided for the year 2008. The forecasted market analysis for 2009-2013 was based on probability of approval and sales of products in late stage development, product marketing, and demographic trends. Some of the trends that affected this market include the following:

Insurance and Reimbursement
Drug Costs
Personalized Medicine
Alliances, Acquisitions and Licensing Agreements
Alcohol’s Affect on Cancer Incidence
Healthy Lifestyles Continue to Show Promise for Cancer Prevention
Marketing and Distribution Trends
Geographical Trends
Elderly Clinical Trial Involvement
Late-Stage Drug Development Trends

Profiles of Twelve Key Competitors

As part of its comprehensive coverage, the following companies are profiled:

AstraZeneca (coverage of Arimidex, Casodex, Faslodex, Zoladex, Iressa, Nolvadex and other products)
Biogen IDEC (coverage of Rituxan and other products)
Bristol-Myers Squibb (coverage of Erbitux, Taxol, Ixempra, Sprycel and other products)
Eli Lilly (coverage of Alimta, Gemzar and other products)
Genentech (coverage of Avastin, Herceptin, Rituxan )
Johnson & Johnson (coverage of Doxil, Velcade, Leustatin)
Merck & Company (coverage of Zolinza and other products)
Novartis (coverage of Femara, Gleevec/Glivec, Tasigna, Sandostatin, Proleukin, Afinitor and other products)
Pfizer (coverage of Camptosar and Sutent)
Roche (coverage of Xeloda, Avastin, MabThera, Herceptin, Tarceva and pipeline drugs)
Sanofi-Aventis (coverage of Taxotere, Eloxatine and others)
Schering-Plough (coverage of Intron A, Timodar/Temodal, Caelyx/Doxil and pipeline plans)

Additional Information

Sanofi, Eli, Schering Dominate Chemotherapy Marketplace, finds Kalorama Report

New York, August 30 2010 — The chemotherapy market is a well-established market and has maintained steady growth over the last decade. Worldwide there are hundreds of chemotherapy products that have been approved for cancer treatment, making this the largest area, in terms of available products, in the cancer therapeutics market. Despite new biologic drugs entering the market and the success of these products in treating cancer and other chronic illnesses, traditional therapies continue to be a first option for many cancer victims. Products such as gemcitabine, pemetrexed, and oxaliplatin are expected to continue to fuel this market as new applications for the use of these products are approved. However, the high side effect rate of many traditional chemotherapy products continues to be a primary concern for market growth and for many patients, is a deterring factor in treatment. Focusing on reducing side effects with chemotherapy will continue to be an advantageous position in new research and product development.

The chemotherapy market is a highly competitive area with hundreds of competitors - from large brand marketers to small niche, generic competitors. The increasing cancer incidence and ever changing patent status of products keeps this market growing. Sanofi-Aventis holds the number one position in this market with an estimated 2008 market share of 33.9%. Both of the company’s lead chemotherapy products, Eloxatin and Taxotere, have remained leaders in the market. Sales from Eloxatin were reported at $2 billion in 2008, while sales of Taxotere are increased to nearly $3 billion for 2008. In addition to the company’s currently marketed products, Sanofi-Aventis continues to enhance its cancer product line and has several promising research and development efforts in place. Additionally, new indications and dosage forms are in development for the company’s current products. Eli Lilly & Company’s presence in the chemotherapy market remains strong due to the success of its products Gemzar and Alimta. Strong performance of the company’s lead chemotherapy products are expected to enhance Eli Lilly’s market position. Schering-Plough continues to grow in market presence with its product Temodar, indicated for brain cancer and other products such as Caelyx securing a 8.8% market share.

About Kalorama Information

Kalorama Information supplies the latest in independent market research in the life sciences, as well as a full range of custom research services. We routinely assist the media with healthcare topics.

CHAPTER ONE: EXECUTIVE SUMMARY: Introduction; Scope and Methodology; Size and Growth of the Market; Issues and Trends Affecting Market; Leading Competitors
CHAPTER TWO: INTRODUCTION: What is Cancer; History and Growth of the Cancer Treatment Market; Growth of Cancer Development; Industry Structure; Life Expectancy and Cancer; Description of Cancers
CHAPTER THREE: CHEMOTHERAPY: Overview; Product Descriptions and Examples; Market Size and Growth; Competitive Analysis
CHAPTER FOUR: HORMONE THERAPY: Overview; Product Descriptions and Examples; Market Size and Growth; Competitive Analysis
CHAPTER FIVE: BIOTHERAPEUTICS: Overview; Product Descriptions and Examples; Market Size and Growth; Competitive Analysis
CHAPTER SIX: WORLD CANCER THERAPIES: TOTAL MARKET SIZE AND FORECAST: Overview; Total Market Size and Forecast; Competitive Landscape
CHAPTER SEVEN: ISSUES AND TRENDS AFFECTING THE CANCER MARKET: Introduction; Insurance and Reimbursement Issues; Cancer Drug Costs; Personalized Medicine; Targeted Cancer Therapy; Pharmacogenomics; Alliances Acquisitions and Licensing Agreements; Patient-Reported Outcomes; Alcohol’s Affect on Cancer Incidence; Healthy Lifestyles Continue to Show Promise for Cancer Prevention; Cancer Trends; Marketing and Distribution Trends; Geographical Trends; Elderly Clinical Trial Involvement; Late-Stage Drug Development Trends
CHAPTER EIGHT: CORPORATE PROFILES: Introduction; AstraZeneca plc; Biogen IDEC, Inc.; Bristol-Myers Squibb Company; Eli Lilly & Company; Genentech, Inc.; Johnson & Johnson; Merck & Company, Inc.; Novartis AG; Pfizer, Inc.; Roche; Sanofi-Aventis; Schering-Plough Corporation
CHAPTER NINE: COMPANY DIRECTORY
LIST OF EXHIBITS
EXECUTIVE SUMMARY: Table 1-1 World Cancer Treatment Market, 2004-2013; Figure 1-1 World Cancer Treatment Market, 2004-2013
INTRODUCTION: Table 2-1 Viruses Associated with Cancer in Humans; Table 2-2 Cancer Therapy Approvals per Year in the United States, 1970-2008; Figure 2-1 Cancer Therapy Approvals per Year in the United States, 1970-2008; Table 2-3 Estimated and Projected World Cancer Incidence by Selected Types of Cancer, 2007 and 2020; Figure 2-2 Estimated and Projected World Cancer Incidence by Selected Types of Cancer, 2007 and 2020; Table 2-4 Cancer Incidence and Mortality by Country 2007; Figure 2-3 Cancer Incidence by Country 2007; Figure 2-4 Cancer Deaths by Country 2007; Table 2-5 Total Cancer Incidence by Sex and Country, 2007; Figure 2-5 Total Cancer Incidence by Sex and Country, 2007; Table 2-6 World Population by Selected Geographical Region, 2007 - 2050; Figure 2-6 World Population by Selected Geographical Region, 2007-2050; Table 2-7 Estimated World Population by Age and Geographical Region, 2007; Figure 2-7 Estimated World Population by Age and Geographical Region, 2007; Table 2-8 Percent Population Over 65 by Year and Region; Figure 2-8 Estimated World Population by Age, 2007 and 2050; Table 2-9 Average Life Expectancy in Years by Country 1980 and 2008; Figure 2-9 Average Life Expectancy in Years by Country 1980 and 2008; Table 2-10 United States Average Years of Life Lost Per Person Dying of Cancer, All Races, Both Sexes, 2004; Table 2-11 United States Estimated Person-Years of Life Lost Due to Cancer, All Races, Both Sexes, 2004; Figure 2-12 Approved Cancer Therapies in the United States by Indication; Table 2-10 Types Of Leukemia; Table 2-11 Types Of Primary Lung Cancer; Table 2-12 Classification Of Non-hodgkin’s Lymphomas; Table 2-13 Malignant Conditions Of The Skin
CHEMOTHERAPY: Table 3-1 Leading Products, 2008; Table 3-2 Newly Approved Chemotherapy Agents and Newly Approved Indications, 2007 through 2009; Table 3-3 World Chemotherapy Market, 2004-2013; Figure 3-1 World Chemotherapy Market, 2004-2013; Table 3-4 World Chemotherapy Market, Market by Product Classification, 2004-2013; Figure 3-2 World Chemotherapy Market; Figure 3-3 World Chemotherapy Market; Figure 3-4 World Chemotherapy Market; Figure 3-5 World Chemotherapy Market; Figure 3-6 World Chemotherapy Market; Figure 3-7 World Chemotherapy Market; Table 3-5 World Chemotherapy Market; Figure 3-8 World Chemotherapy Market; Table 3-6 World Chemotherapy Market, Leading Suppliers Shares by Market Revenues, 2008; Figure 3-9 World Chemotherapy Market, Leading Suppliers Market Share, 2008
HORMONE THERAPY: Table 4-1 Leading Products, 2008; Table 4-2 Newly Approved Hormone Cancer Therapies and Additional Indications 2007 through 2009; Table 4-3 World Hormone Therapy Market, 2004-2013; Figure 4-1 World Hormone Therapy Market, 2004-2013; Table 4-4 World Hormone Therapy Market, Market by Product Classification, 2004-2013; Figure 4-2 World Hormone Therapy Market, Market by Product Classification Revenues, 2004-2013; Figure 4-3 World Hormone Therapy Market, Market by Product Classification and Percent Distribution, 2004-2013; Figure 4-4 World Hormone Therapy Market, Market by Product Classification and Percent Market Share, 2008; Figure 4-5 World Hormone Therapy Market, Market by Product Classification and Percent Market Share, 2013; Figure 4-6 World Hormone Therapy Market; Figure 4-7 World Hormone Therapy Market; Table 4-5 World Hormone Therapy Market; Figure 4-8 World Hormone Therapy Market; Table 4-6 World Hormone Therapy Market, Leading Suppliers Shares by Market Revenues, 2008; Figure 4-9 World Hormone Therapy Market, Leading Suppliers Market Share, 2008
BIOTHERAPEUTICS: Table 5-1 Leading Products, 2008; Table 5-2 Newly Approved Biological Therapies and Additional Indications, 2007 through March 2009; Table 5-3 World Cancer Biotherapeutics Market, 2004-2013; Figure 5-1 World Cancer Biotherapeutics Market, 2004-2013; Table 5-4 World Cancer Biotherapeutics Market Market by Product Type, (Monoclonal Antibodies, Interleukins/ Interferons, Other) 2004-2013; Figure 5-2 World Cancer Biotherapeutics Market, Market by Product Classification (Monoclonal Antibodies, Interleukins/ Interferons, Other) OtherRevenues, 2004-2013; Figure 5-3 World Cancer Biotherapeutics Market, Market by Product Classification and Percent Distribution, 2004-2013; Figure 5-4 World Cancer Biotherapeutics Market, Market by Product Classification and Percent Market Share, 2008; Figure 5-5 World Cancer Biotherapeutics Market, Market by Product Classification and Percent Market Share, 2013; Figure 5-6 World Cancer Biotherapeutics Market; Figure 5-7 World Cancer Biotherapeutics Market; Table 5-5 World Cancer Biotherapeutics Market; Figure 5-8 World Cancer Biotherapeutics Market; Table 5-6 World Biotherapeutics Market, Leading Suppliers Shares by Market Revenues, 2008; Figure 5-9 World Cancer Biotherapeutics Market, Leading Suppliers Market Share, 2008
WORLD CANCER THERAPIES: TOTAL MARKET SIZE AND FORECAST: Table 6-1 World Cancer Market Market by Product Type, 2004-2013; Figure 6-1 World Cancer Market, Market by Product Type Revenues, 2004-2013; Figure 6-2 World Cancer Market, Market by Product Type and Percent Distribution, 2004-2013; Figure 6-3 World Cancer Market, Market by Product Type and Percent Market Share, 2008; Figure 6-4 World Cancer Market, Market by Product Type and Percent Market Share, 2013; Table 6-2 World Cancer Market, Top Five Suppliers Shares by Market Revenues, 2008; Figure 6-5 World Cancer Market, Top Five Suppliers Market Share, 2008 Issues and Trends Affecting the Cancer Market
ISSUES AND TRENDS AFFECTING THE CANCER MARKET: Table 7-1 Obesity Rates by State; Table 7-2 Select Products in Development by Product Name; Figure 7-1 Late Stage Cancer Compounds in Development for Major Indications
CORPORATE PROFILES: Figure 8-1 Late stage Cancer Therapies in Development for Leading Companies

More Global Oncology/Hematology Reports

2012 Global CA Tumor Markers Diagnostics Market Outlook: Test Volumes, Sales Forecasts, and Supplier Shares by Country by Venture Planning Group
The cancer diagnostics market is on the verge of explosion, as the researchers approach major technological breakthroughs in tumor diagnosis and therapy, discover new specific ...

2012 World Cancer Diagnostic Market Overview: Facilities, Test Volumes, and Sales Forecasts by Country by Venture Planning Group
This report provides a worldwide overview of the cancer diagnostics market, including mortality statistics and scientific views on the etiology of major types of cancer, ...

Cancer Pain Global Clinical Trials Review, H1, 2012 by GlobalData
Cancer Pain Global Clinical Trials Review, H1, 2012 Summary GlobalData's clinical trial report, “Cancer Pain Global Clinical Trials Review, H1, 2012 provides data on the Cancer Pain ...

The 2012 Global Cancer Diagnostic Market Overview - Facilities, Test Volumes, and Sales Forecasts by Country by Venture Planning Group
This report provides a worldwide overview of the cancer diagnostics market, including mortality statistics and scientific views on the etiology of major types of cancer, ...

World Market for Prescription Dermatological Drugs, 8th Edition (Antiacne, Antiaging, Dermatitis, Hair Loss, Psoriasis, Skin Cancer, Melasma and Seborrhea Treatments) by Kalorama Information
This Kalorama Information report, The Worldwide Market for Prescription Dermatological Drugs represents the eighth time that Kalorama has detailed the various categories of prescription dermatological ...

See all reports like this >>

The World Market for Cancer Therapeutics and Biotherapeutics, 3rd. Edition

Share this report

Other tasks

Research Assistance

Related Markets

Oncology/Hematology Reports

Free Alert Me service